Plain-English translation of NCT07656415 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help reduce the number of blood transfusions that people with sickle cell disease need. Sickle cell disease causes red blood cells to become hard and sticky, which can block blood vessels and damage organs. Many patients need regular blood transfusions to help manage their condition, but this medication may help reduce that need.
People with sickle cell disease often need frequent blood transfusions, which can lead to serious complications and affect quality of life. Researchers are testing this new treatment to see if it can help by improving how well red blood cells function, potentially reducing or delaying the need for transfusions.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take the medication (or a placebo that looks identical) by mouth twice a day for up to one year. You'll have regular clinic visits to check your blood work, transfusion needs, and how you're doing. Half the participants will receive the actual medication and half will receive a placebo, and neither you nor your doctor will know which one you're getting during the first year. If the medication appears to be working, you may be able to continue taking it for another year in an open-label extension phase.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States